All In MedTech

Device Trial Radar · NCT02682420

everlinQ endoAVF Post Market Study

Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

100

Actual

Start

Sep 20, 2016

Primary completion

Aug 2019

Study completion Aug 2019

Sponsor

Lead sponsor
C. R. BardPublic (BDX)
Sponsor type
Industry
First posted
Feb 15, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multi-center study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for hemodialysis.

Conditions

  • Chronic Kidney Disease

Interventions

  • everlinQ endoAVF SystemDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Primary Patency of the endoAVF at 6 Months Post-Index ProcedureTime frame: endoAVF creation through 6 months

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Providence Health Care Society

    Vancouver, British Columbia, Canada

10 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.